Florence Roufosse

7.1k total citations · 3 hit papers
88 papers, 4.2k citations indexed

About

Florence Roufosse is a scholar working on Rheumatology, Surgery and Immunology. According to data from OpenAlex, Florence Roufosse has authored 88 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Rheumatology, 60 papers in Surgery and 36 papers in Immunology. Recurrent topics in Florence Roufosse's work include Eosinophilic Disorders and Syndromes (77 papers), Eosinophilic Esophagitis (58 papers) and Immune Cell Function and Interaction (15 papers). Florence Roufosse is often cited by papers focused on Eosinophilic Disorders and Syndromes (77 papers), Eosinophilic Esophagitis (58 papers) and Immune Cell Function and Interaction (15 papers). Florence Roufosse collaborates with scholars based in Belgium, United States and United Kingdom. Florence Roufosse's co-authors include Elie Cogan, Peter F. Weller, Michel Goldman, Gerald J. Gleich, Amy D. Klion, Hans‐Uwe Simon, Marc E. Rothenberg, Jean‐Emmanuel Kahn, Liliane Schandené and Lanny J. Rosenwasser and has published in prestigious journals such as New England Journal of Medicine, Blood and Annual Review of Immunology.

In The Last Decade

Florence Roufosse

81 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

2012 457 citations Amy D. Klion, Florence Roufosse et al. Journal of Allergy and Clinical Immunology profile →
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

2008 403 citations Marc E. Rothenberg, Amy D. Klion et al. New England Journal of Medicine profile →
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

2024 69 citations Michael E. Wechsler, Parameswaran Nair et al. New England Journal of Medicine profile →

Peers

Florence Roufosse

RHEUM

SURGE

PRM

IMMUN

PHYSI

Jean‐Emmanuel Kahn France

Divi Cornec France

Achille Aouba France

B Jarrousse France

L Guillevin France

Peter Lamprecht Germany

Karim Sacré France

Nancy B. Allen United States

Karyl S. Barron United States

Syuji Takei Japan

Jean‐Emmanuel Kahn France

Florence Roufosse

1.5k ×0.5

RHEUM

1.0k ×0.4

SURGE

1.0k ×0.7

PRM

751 ×0.6

IMMUN

646 ×0.7

PHYSI

Citations per year, relative to Florence Roufosse Florence Roufosse (= 1×) peers Jean‐Emmanuel Kahn

Countries citing papers authored by Florence Roufosse

Since Specialization

Citations

This map shows the geographic impact of Florence Roufosse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Roufosse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Roufosse more than expected).

Fields of papers citing papers by Florence Roufosse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Roufosse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Roufosse. The network helps show where Florence Roufosse may publish in the future.

Co-authorship network of co-authors of Florence Roufosse

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Roufosse. A scholar is included among the top collaborators of Florence Roufosse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Roufosse. Florence Roufosse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moutschen, Michel, Cécile Boulanger, Joke Dehoorne, et al.. (2025). Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study. BMC Rheumatology. 9(1). 64–64.

Hellmich, Bernhard, Arnaud Bourdin, David Jayne, et al.. (2025). The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 78(3). 695–704.

Lelubre, Christophe, et al.. (2025). Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A multicenter prospective study. Journal of Allergy and Clinical Immunology. 155(4). 1299–1309. 1 indexed citations

Wechsler, Michael E., Parameswaran Nair, Benjamin Terrier, et al.. (2024). Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine. 390(10). 911–921. 69 indexed citations breakdown →

Buchheit, Kathleen M., Dominick Shaw, Geoffrey Chupp, et al.. (2024). Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils. Allergy. 79(10). 2662–2679. 21 indexed citations

Specks, Ulrich, Michael E. Wechsler, David J. Jackson, et al.. (2024). Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Open-label Extension Period of the Phase 3 MANDARA Study. A5358–A5358. 1 indexed citations

Khoury, Paneez, Praveen Akuthota, Namhee Kwon, Jonathan Steinfeld, & Florence Roufosse. (2023). HES and EGPA. Mayo Clinic Proceedings. 98(7). 1054–1070. 16 indexed citations

Bondue, Antoine, et al.. (2023). Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome. Frontiers in Cardiovascular Medicine. 10. 1256862–1256862. 1 indexed citations

Bondue, Antoine, et al.. (2021). Hypereosinophilic syndrome: considerations for the cardiologist. Heart. 108(3). 164–171. 19 indexed citations

10.

Roufosse, Florence, et al.. (2021). What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?. Seminars in Immunopathology. 43(3). 439–458. 32 indexed citations

11.

Roufosse, Florence, Jean‐Emmanuel Kahn, Marc E. Rothenberg, et al.. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 146(6). 1397–1405. 111 indexed citations

12.

Roufosse, Florence. (2018). Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. Frontiers in Medicine. 5. 49–49. 144 indexed citations

13.

Roufosse, Florence. (2015). Management of Hypereosinophilic Syndromes. Immunology and Allergy Clinics of North America. 35(3). 561–575. 20 indexed citations

14.

Roufosse, Florence. (2013). L4. Eosinophils: How they contribute to endothelial damage and dysfunction. La Presse Médicale. 42(4). 503–507. 12 indexed citations

15.

Klion, Amy D., Florence Roufosse, Jean‐Emmanuel Kahn, et al.. (2012). Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome. Journal of Allergy and Clinical Immunology. 129(2). AB203–AB203. 1 indexed citations

16.

Wechsler, Michael E., Patricia C. Fulkerson, Bruce S. Bochner, et al.. (2012). Novel targeted therapies for eosinophilic disorders. Journal of Allergy and Clinical Immunology. 130(3). 563–571. 77 indexed citations

17.

Huez, Sandrine, Florence Roufosse, J‐L. Vachiéry, et al.. (2007). Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?. European Respiratory Journal. 30(5). 928–936. 49 indexed citations

18.

Vanthuyne, Marie, Frédéric Houssiau, Daniël Blockmans, et al.. (2006). Efficacy and safety of a protocol-based treatment of severe early diffuse systemic sclerosis (dSSc) using mycophenolate mofetil (MMF) in combination with intravenous methylprednisolone (IV MP) pulses.. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 54(9). 1 indexed citations

19.

Lavareille, Aurore de, Florence Roufosse, Peter Schmid‐Grendelmeier, et al.. (2002). High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology. 110(3). 476–479. 64 indexed citations

20.

Roufosse, Florence, Liliane Schandené, Elie Cogan, & Michel Goldman. (2000). Hypereosinophilies chroniques: Un modele de maladie Th2. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 50(6). 622–626. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact